search button

Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells

  • Authors:
    • Vincent Lucansky
    • Monika Krmencikova-Fliegl
    • Libor Stanek
    • Vladimir Vonka

  • View Affiliations

  • Published online on: July 28, 2014     https://doi.org/10.3892/mmr.2014.2425
  • Pages: 2116-2122
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Stromal‑derived factor 1α (SDF‑1α, also known as CXCL12) is a chemokine that exerts its effects through the G‑protein coupled receptors, C‑X‑C chemokine receptor type 4 (CXCR4) and 7 (CXCR7). There is marked evidence that the SDF‑1/CXCR4 axis is involved in the pathogenesis of leukemia and therapies that target this axis are under development. The present study aimed to increase the efficacy of a DNA‑based bcr‑abl vaccine by simultaneously immunizing mice with a plasmid carrying the whole SDF‑1α gene. Bcr‑abl‑transformed 12B1 cells were used to challenge the mice. These cells have the oncogenic potential to induce both leukemia following intravenous inoculation and lymphoma‑type solid tumors after subcutaneous inoculation. Administering an SDF‑1 carrying plasmid together with the bcr‑abl vaccine resulted in increased survival following a challenge with subcutaneously administered 12B1 cells, although the difference was not statistically significant. However, there was a difference when the animals that developed subcutaneous tumors were only taken into consideration. In doubly‑treated mice, significantly more mice failed to develop solid tumors than mice that had only received the bcr‑abl vaccine. By contrast, the occurrence of fatal leukemia was significantly higher in the mice that were treated with the SDF‑1 plasmid, regardless of whether they were immunized with the bcr‑abl‑vaccine. No humoral or cellular immune responses against SDF‑1 were detected in the treated mice, which suggested that the changes in oncogenic potential of 12B1 cells were due to the activity of SDF‑1 itself.
View Figures
View References

Related Articles

Journal Cover

October 2014
Volume 10 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 3.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
  • CiteScore: 6.9
  • CiteScore Rank: Q2: #98/328 Biochemistry, Genetics and Molecular Biology
  • Source Normalized Impact per Paper (SNIP): 0.721
  • SCImago Journal Rank (SJR): 0.65
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Lucansky V, Krmencikova-Fliegl M, Stanek L and Vonka V: Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells. Mol Med Rep 10: 2116-2122, 2014
APA
Lucansky, V., Krmencikova-Fliegl, M., Stanek, L., & Vonka, V. (2014). Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells. Molecular Medicine Reports, 10, 2116-2122. https://doi.org/10.3892/mmr.2014.2425
MLA
Lucansky, V., Krmencikova-Fliegl, M., Stanek, L., Vonka, V."Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells". Molecular Medicine Reports 10.4 (2014): 2116-2122.
Chicago
Lucansky, V., Krmencikova-Fliegl, M., Stanek, L., Vonka, V."Administration of a plasmid that expresses SDF-1α affects the oncogenic potential of mouse bcr-abl-transformed cells". Molecular Medicine Reports 10, no. 4 (2014): 2116-2122. https://doi.org/10.3892/mmr.2014.2425